Haematology is a complex discipline. Whether you're dealing with a blood cancer or a chronic benign disorder, the decisions come fast, the data is dense, and the stakes are deeply personal. Every diagnosis — leukaemia, aplastic anaemia, an immune-mediated condition — carries layers of biological nuance and long-term consequences.
AI has started to change how we work in this field, and the promise is real: faster diagnoses, sharper insights, more personalised treatment. But the more useful question isn't whether AI belongs in haematology — it clearly does — it's how carefully we bring it in.
The most immediate use is in diagnostics. So much of haematology comes down to reading subtle signals — blood counts, cell morphology, flow cytometry patterns, genetic markers. AI tools are getting genuinely good at analysing blood smears and bone marrow biopsies, catching things that might slip past even experienced eyes in a busy, high-volume setting.
This matters most where specialist access is thin. In resource-limited environments, even cutting diagnostic delays by a few days can change outcomes in conditions where early treatment is everything.
For your daily dose of medical news and updates, visit: HEALTH
The relevance of AI isn't limited to cancers, either. Benign haematology and immunology — thalassemia, sickle cell disease, immune cytopenias — involve lifelong management and constant clinical judgment calls. AI can help predict how a disease will behave, flag complications before they escalate, and guide decisions around transfusions or immunotherapy. In immunology, especially, where the immune system can dysregulate in overlapping and confusing ways, AI's ability to spot patterns across clinical, lab, and genetic data can mean earlier recognition and more targeted care.
The deeper potential, though, lies in synthesis. Modern haematology generates staggering amounts of data — genomics, proteomics, treatment histories, long-term outcomes. No clinician can hold all of that in their head at once. AI can find the correlations we'd miss, sharpen risk stratification, and help us make sense of the molecular and genetic profiles that increasingly drive treatment decisions in blood cancers.
There are also more experimental frontiers. In cellular therapy, AI is being used to design better engineered immune cells — improving their precision, durability, and safety. Early results are encouraging, and development timelines are shortening. And this isn't just a story about well-funded Western research centres; Indian institutions and startups are meaningfully part of this work.
That said, there are real problems we shouldn't paper over. AI is only as good as the data it's trained on. Models built on limited or unrepresentative datasets will struggle with the extraordinary genetic and clinical diversity of a population like India's — they may misclassify, underdiagnose, or recommend the wrong treatment. That's not a theoretical risk; it's a practical one.
But here's the flip side: that same diversity, if properly captured and studied, makes India a remarkable place to build more inclusive and generalisable algorithms. The opportunity is there — it just requires systematic data collection, rigorous validation, and clinicians who stay actively in the loop rather than deferring to outputs uncritically.
Staying in the loop matters because haematology involves trade-offs that data alone can't resolve. How do you weigh treatment efficacy against toxicity for a particular patient? How does quality of life factor in? What are the patient's own priorities, and what practical constraints — financial, familial, logistical — shape what's actually possible? AI can inform these conversations, but it can't have them.
The ethical and regulatory side of things also needs more attention than it currently gets. Data privacy, informed consent, algorithmic transparency, accountability when something goes wrong — these aren't niche concerns. As AI embeds itself more deeply into clinical workflows, governance frameworks need to keep pace.
Still, none of this cancels out what AI genuinely offers — particularly in settings where specialists are scarce, and care is uneven. It can raise the floor, reduce variability, and give clinicians better tools to work with more complex information than any of us could manage alone.
What it cannot do is sit with a patient and their family at a frightening moment. It cannot offer reassurance, absorb anxiety, or carry the weight of a difficult conversation. Haematology, at its core, is about guiding people through some of the hardest experiences of their lives — often across months or years of treatment. No model does that.
AI doesn't need to. That's not its job. Its job is to make the clinical side sharper, so the human side has more room to breathe.
The future here isn't human versus machine. It's both, working together — with clear eyes about what each does well, and what each cannot do at all.
The writer is a paediatric haematologist and a bone marrow transplant specialist in New Delhi. He is also a researcher innovating cell therapy solutions.
The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.